PuSH - Publication Server of Helmholtz Zentrum München

Maalmi, H.* ; Strom, A.* ; Petrera, A. ; Hauck, S.M. ; Strassburger, K.* ; Kuss, O.* ; Zaharia, O.P.* ; Bönhof, G.J.* ; Rathmann, W.* ; Trenkamp, S.* ; Burkart, V.* ; Szendroedi, J. ; Ziegler, D.* ; Roden, M.* ; Herder, C.*

Serum neurofilament light chain: A novel biomarker for early diabetic sensorimotor polyneuropathy.

Diabetologia 66, 579-589 (2022)
Publ. Version/Full Text Research data DOI PMC
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Aims/hypothesis: No established blood-based biomarker exists to monitor diabetic sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament light chain (NFL), a blood biomarker of neuroaxonal damage in several neurodegenerative diseases, represents a potential biomarker for DSPN. We hypothesised that higher serum NFL levels are associated with prevalent DSPN and nerve dysfunction in individuals recently diagnosed with diabetes. Methods: This cross-sectional study included 423 adults with type 1 and type 2 diabetes and known diabetes duration of less than 1 year from the prospective observational German Diabetes Study cohort. NFL was measured in serum samples of fasting participants in a multiplex approach using proximity extension assay technology. DSPN was assessed by neurological examination, nerve conduction studies and quantitative sensory testing. Associations of serum NFL with DSPN (defined according to the Toronto Consensus criteria) were estimated using Poisson regression, while multivariable linear and quantile regression models were used to assess associations with nerve function measures. In exploratory analyses, other biomarkers in the multiplex panel were also analysed similarly to NFL. Results: DSPN was found in 16% of the study sample. Serum NFL levels increased with age. After adjustment for age, sex, waist circumference, height, HbA1c, known diabetes duration, diabetes type, cholesterol, eGFR, hypertension, CVD, use of lipid-lowering drugs and use of non-steroidal anti-inflammatory drugs, higher serum NFL levels were associated with DSPN (RR [95% CI] per 1-normalised protein expression increase, 1.92 [1.50, 2.45], p<0.0001), slower motor (all p<0.0001) and sensory (all p≤0.03) nerve conduction velocities, lower sural sensory nerve action potential (p=0.0004) and higher thermal detection threshold to warm stimuli (p=0.023 and p=0.004 for hand and foot, respectively). There was no evidence for associations between other neurological biomarkers and DSPN or nerve function measures. Conclusions/interpretation: Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN. Graphical abstract: [Figure not available: see fulltext.]
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Axonal Damage ; Biomarker ; Demyelination ; Diabetes ; Diabetic Neuropathy ; Diabetic Sensorimotor Polyneuropathy ; Distal Sensorimotor Polyneuropathy ; Electrophysiological Tests ; Large Fibre ; Nerve Conduction Study ; Nerve Dysfunction ; Nerve Injury ; Neurofilament Light Chain ; Neurofilaments ; Neurological Biomarkers ; Peripheral Nervous System ; Peripheral Neuropathy ; Quantitative Sensory Tests ; Small Fibre; Diagnostic-criteria; Nerve-conduction; Definition; Neuropathy; Update
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Journal Diabetologia
Quellenangaben Volume: 66, Issue: 3, Pages: 579-589 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Berlin ; Heidelberg [u.a.]
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) CF Metabolomics & Proteomics (CF-MPC)
Institute of Diabetes and Cancer (IDC)
Grants SMH
DZD
German Federal Ministry of Educationand Research (Berlin, Germany
Ministry of Cultureand Science of the state of North Rhine-Westphalia (Duesseldorf,Germany)
GermanFederal Ministry of Health (Berlin, Germany)
German Diabetes Center (DDZ)
ProjektDEAL